Literature DB >> 21416481

In vitro efficacy of tyrosine kinase inhibitors: SYK and BCR-ABL inhibitors in lymphomas.

Andrea Rinaldi, Maurilio Ponzoni, Silvia Uccella, Davide Rossi, Gianluca Gaidano, Fabio Facchetti, Giancarlo Pruneri, Maria Grazia Tibiletti, Carlo Capella, Emanuele Zucca, Claudio Doglioni, Carlo Catapano, Francesco Bertoni.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21416481     DOI： 10.1002/hon.981

Source DB:  PubMed          Journal:  Hematol Oncol        ISSN： 0278-0232            Impact factor:   5.271


× No keyword cloud information.
  2 in total

1.  SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas.

Authors:  Linfeng Chen; Stefano Monti; Przemyslaw Juszczynski; Jing Ouyang; Bjoern Chapuy; Donna Neuberg; John G Doench; Agata M Bogusz; Thomas M Habermann; Ahmet Dogan; Thomas E Witzig; Jeffery L Kutok; Scott J Rodig; Todd Golub; Margaret A Shipp
Journal:  Cancer Cell       Date:  2013-06-10       Impact factor: 31.743

2.  An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma.

Authors:  John M Burke; Andrei Shustov; James Essell; Dipti Patel-Donnelly; Jay Yang; Robert Chen; Wei Ye; Wen Shi; Sarit Assouline; Jeff Sharman
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2018-06-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.